Johnson & Johnson (Canada) Inc.
Registration:
2
of
3
(2023-12-29
to
2024-05-04)
Details Regarding the Identified Subject Matter
|
Specific Topics of Lobbying Communications
|
Intended Outcomes
|
Associated Subject Matters
|
Communications regarding obesity care pathway strategies.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Economic Development and Trade, Health, Hospitals, Science and Technology
|
Policies and legislation related to healthcare delivery and domestic manufacturing of drugs and therapeutic products, and deployment of solutions and services in the healthcare field. Johnson & Johnson (Canada) Inc. supports the development of a strong life science strategy and emerging policies that may impact the life sciences ecosystem in British Columbia. These communications may also focus on policies and legislation impacting the evaluation, marketing, sale, funding, procurement and use of pharmaceutical therapeutic products as well as medical devices and solutions and services in the healthcare field in British Columbia.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity, Development of any legislative proposal by the government of British Columbia, a Provincial entity or a member of the Legislative Assembly, Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
|
Economic Development and Trade, Health, Hospitals, Science and Technology
|